UK news

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Massive hope for pancreatic cancer pill after trial saw tumours vanish

Cancer Research UK has described the recent advancement in pancreatic cancer treatment as “the biggest leap forward in decades” for patients suffering from this disease. Dr. Sam Godfrey, representing the charity, shared with BBC News how thrilling the findings are, emphasizing the significance of this new drug, which manages to target what was previously deemed “undruggable.” He expressed optimism, saying, “We are finally seeing progress in pancreatic cancer which is so long overdue.”

Pancreatic cancer is known for being exceptionally difficult to manage, with the UK reporting the lowest survival rates among common cancers. Chemotherapy, while able to somewhat reduce tumor size, often fails to prevent regrowth of the cancer. Those diagnosed with advanced stages typically have survival measured in months rather than years. The introduction of this new treatment offers a glimmer of hope, potentially extending patients’ survival even if it cannot completely eradicate the disease. The clinical trial monitored patients for an average period of 18 months, revealing that some individuals did not experience a recurrence of their cancer during that time. While encouraging, researchers stress the need for longer-term studies to determine whether remission is achievable and for how long it might last.

During the trial, results showed remarkable outcomes: tumor growth was halted in 90% of participants, over 60% saw their tumors shrink or vanish, and for about 8%—roughly one in twelve patients—the tumors could no longer be detected using CT scans. Dr. Wungki Park, a researcher from the Memorial Sloan Kettering Cancer Center in the United States who is involved in the study, described the findings as “extremely encouraging.” He highlighted improvements not only in the rates at which tumors responded but also in the depth of those responses and nearly doubled duration of disease control, factors that may eventually translate into prolonged survival.

The drug at the center of these breakthroughs is Daraxonrasib, a KRAS inhibitor already approved in the US. It functions by specifically targeting RAS mutations — genetic alterations responsible for driving tumor growth in most pancreatic cancers. Since many other cancer types, such as lung and ovarian cancers, share similar mutations, this treatment has the potential to aid a wider group of patients beyond those with pancreatic cancer. Dr. Godfrey expressed hope that the success seen in pancreatic cancer might soon be replicated in other cancer treatments. Experts like Professor Elena Garralda, who chairs a European cancer organization focused on research, underscored the excitement around the data, noting the combination therapy’s potential to significantly improve overall survival and delay tumor progression.

Each year in the UK, around 11,500 people receive a pancreatic cancer diagnosis, with approximately 10,200 succumbing to the disease, according to Cancer Research UK. The disease gained public attention when actor Alan Rickman passed away from pancreatic cancer in 2016, just five months after his diagnosis. Common symptoms linked to pancreatic cancer can include jaundice, itching, darker urine, pale stools, unexplained weight loss, fatigue, and fever

Read the original at The BBC

On air now

Low-Fi Lounge

It Feels So GoodSonique · Low-Fi Lounge

LIVE